A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2002
10/30/2002	CN1377344A Inhibitor of cysteinyl aspartic acid proteinase
10/30/2002	CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002	CN1377277A Use of leptin in inhibition of endothelial cell proliferation
10/30/2002	CN1377269A Vitronectin receptor antagonists
10/30/2002	CN1377268A Cell adhesion inhibitors
10/30/2002	CN1377259A ACE-2 inhibiting compounds and methods of use thereof
10/30/2002	CN1377252A Composition for restoring defects in calcified tissues
10/30/2002	CN1376516A Injection-type compound bone repairing material containing more biological factors and using animal fibrin as carrier
10/30/2002	CN1376514A Injection-type bone morphogenetic protein using fibrin as carrier
10/30/2002	CN1376510A Powdered medicine for setting bone and relieving rigidity of tendon and muscles
10/30/2002	CN1376504A Intravenous injection of Chinese angelica root and its preparing process
10/30/2002	CN1376500A Capsule 'Jingyaoning' and its preparing process
10/30/2002	CN1376499A Capsule 'Qianggukang' for strengthening bone and its preparing process
10/30/2002	CN1376476A Wulong Dan for activating collaterals and strengthening tendon and muscles
10/30/2002	CN1376475A Medicine for threating rheumatism, rheumatoid disease, lumbar intervertebral disk protrusion, hyperosteogeny and ischias and its preparing process
10/30/2002	CN1376474A Bone-setting pill 'Jiegudan'
10/30/2002	CN1376470A Ointment for dispelling wind and relieving rigidity of muscles and joints and its preparing process
10/30/2002	CN1093410C Process for preparing medical wine to treat rheumatic arthritis
10/30/2002	CN1093409C Fracture treating plaster
10/30/2002	CA2383662A1 Methods and products for identifying modulators of p2x7 receptor activity, and their use in the treatment of skeletal disorders
10/30/2002	CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002	US6472505 Treatment of physiological conditions capable of being modulated by agonist or antagonist activity on parathyroid hormone receptors
10/29/2002	US6472418 Non-peptide NK1 receptors antagonists
10/29/2002	US6472412 Compounds as PDE IV and TNF inhibitors
10/29/2002	US6472403 αV integrin receptor antagonists
10/29/2002	US6472396 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/29/2002	US6472382 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them
10/29/2002	US6472379 Angiogenesis inhibition
10/29/2002	US6472179 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia
10/29/2002	US6471997 Antagonist of calcitonin gene related peptide, cgrp and/or of substance p; cosmetic
10/29/2002	CA2173102C Dna sequence coding for a bmp receptor
10/24/2002	WO2002084249A2 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	WO2002083926A2 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	WO2002083879A2 Immunotherapy based on dendritic cells
10/24/2002	WO2002083874A2 Endothelial cell expression patterns
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083734A2 Modified calcitonin
10/24/2002	WO2002083733A2 Polynucleotides and polypeptides of the ifnalpha-6 gene
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083700A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	WO2002083696A2 Novel cyclo azaphospha hydrocarbons
10/24/2002	WO2002083693A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083159A1 Palliative effects of morinda citrifolia oil and juice
10/24/2002	WO2002083151A2 Compositions and methods for treating an arthritic condition
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	WO2002083127A1 Protein modification-inhibitory compositions
10/24/2002	WO2002083106A1 Controlled delivery of tetracycline compounds and tetracycline derivatives
10/24/2002	WO2002083075A2 Akt and regulation of ra synovial fibroblast apoptosis
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002083058A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2002026258A3 Treatment of immune-mediated diseases by oral administration of plasma fractions
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156266 Sodium phosphate cotransporter expressed on apical surface of intestinal epithelial cells (huNpt2B) and polypeptides related thereto
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156101 Use for pain management
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156074 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors
10/24/2002	US20020156071 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156040 Antisense oligonucleotides that bind to the enzyme's start codon; inhibiting enzymes such as superoxide dismutase
10/24/2002	US20020156031 A DNA segment comprising a protein coding region encoding an Osterix polypeptide; gene therapy; osteoporosis; recombinant Osterix polypeptide
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156024 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/24/2002	US20020156001 Novel fibroblast growth factor ( FGF23) and methods for use
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155115 Cancer therapy
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2770489A1 Bisphosphonate conjugates and methods of making and using the same

1 ... 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 ... 820